Type 2 diabetes mellitus (T2DM) is a major risk factor
|
|
- Lee Stevens
- 5 years ago
- Views:
Transcription
1 Review Summary Coronary Artery Disease and Type 2 Diabetes Mellitus Current Treatment Strategies and Future Perspective Ryo Naito, 1 MD and Katsumi Miyauchi, 2 MD Type 2 diabetes mellitus (T2DM) is a major risk factor of coronary artery diseases (CAD). Clinical outcomes in CAD with T2DM are poor despite improvement in medications and intervention devices. Coronary artery bypass grafting (CABG) is superior to percutaneous coronary intervention (PCI) in treating diabetic patients with multivessel coronary artery diseases (MVD). However, selecting a revascularization strategy should depend not only on the lesion complexity but also on the patient s background and comorbidities. In addition, comprehensive risk management with medical and non-pharmacological therapies is important, as is confirmation of whether risk managements are appropriately achieved. Recently, novel anti-diabetic drugs have been demonstrated to have effectiveness in reducing cardiovascular events, which was independent of their glucose-lowering effect. Furthermore, non-pharmacological interventions using exercise and diet during the earlier stages of abnormal glucose metabolism might be beneficial in preventing the development or progression of T2DM and reducing the incidence of cardiovascular events. (Int Heart J 2017; 58: ) Key words: Multivessel disease, Revascularization, SGLT2 inhibitor, GLP1 antagonist, Comprehensive risk management Type 2 diabetes mellitus (T2DM) is a major risk factor affecting coronary artery disease (CAD). 1) In addition, 75% of T2DM patients die as a consequence of cardiovascular diseases, including CAD. 2) In patients with T2DM, CAD is more likely to be a complex disease characterized by small, diffuse, calcified, multivessel disease (MVD) 3,4) and often requires coronary revascularization in addition to optimal medical therapy to control angina. 5) Regarding coronary revascularization, recent advances in the techniques and devices related to percutaneous coronary intervention (PCI) have expanded the indication of PCI to more complex lesions. 6-8) Drug-eluting stents (DES) in particular have dramatically reduced the rate of restenosis and repeat revascularization. 9,10) However, the morbidity and mortality of CAD in patients with T2DM continues to be high, even in this current DES era. 11) Although most clinical trials comparing outcomes among T2DM patients with MVD have shown that coronary artery bypass grafting (CABG) was superior to PCI in terms of the lower repeat revascularization rate and lower incidences of myocardial infarction and mortality, 12-14) it is not practical to perform CABG in all diabetic patients with MVD. Because CABG is highly invasive in contrast to PCI, selection of each revascularization therapy should depend on not only the lesion complexity but also a patient s characteristics and comorbidities. In clinical trials, higher-risk surgical patients, such as the elderly and those with more comorbid diseases, have not been included. Therefore, selecting a revascularization therapy for CAD with T2DM requires a thorough discussion of the lesion characteristics and patient characteristics including age, comorbidities, cardio-pulmonary function, and frailty. Recently, novel anti-diabetic drugs have been demonstrated to have effectiveness on reducing cardiovascular events, which was independent of the glucose-lowering effect. Furthermore, non-pharmacological interventions using exercise and diet during earlier stages of abnormal glucose metabolism might be beneficial in preventing the development or progression of T2DM and reducing the incidence of cardiovascular events. Here, we provide novel insights into the following important and unresolved issues: 1) efficacy of the newer DESs in terms of repeat revascularization, incidences of myocardial infarction and mortality compare to CABG, and 2) what is the optimal medical therapy considering the positive results of novel anti-diabetic agents. Revascularization Therapy Advances in PCI have prompted its use in more complex lesions that had been previously indicated for CABG. However, MVD in T2DM patients is associated with a high incidence of repeat revascularization after PCI with DES; therefore, CABG remains superior to PCI in such lesions. A meta-analy- From the 1 Heart Center, Juntendo University Urayasu Hospital, Chiba and 2 Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan. Address for correspondence: Katsumi Miyauchi, MD, Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Hongo Bunkyo-ku, Tokyo , Japan. ktmmy@juntendo.ac.jp Received for publication April 5, Accepted April 10, Released in advance online on J-STAGE July 14, All rights reserved by the International Heart Journal Association. 475
2 476 NAITO, ET AL Int Heart J July 2017 sis has demonstrated that the superiority of CABG to PCI with balloon angioplasty or bare metal stents in terms of all-cause mortality was greater in patients with than without T2DM. 15) Several clinical trials have been conducted in the United States and Europe to compare CABG with PCI using DES. The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study was a prospective randomized trial that compared the efficacy of CABG and PCI with paclitaxel-eluting stents (PES) in patients with de novo left main coronary disease, 3-vessel disease, or both, which were considered equally suitable for CABG or PCI by both a cardiac surgeon and an interventional cardiologist at each center. 16) In the trial, 452 (25.1%) patients were diabetic and were included in a pre-specified sub-analysis. For the 3-year major adverse cardiac and cerebrovascular events in the diabetic cohort, the incidence was 37.0% and 22.9% in the PCI group and CABG group (P = 0.002), respectively. The rate of revascularization was also higher in the PCI group (PCI, 28.0% and CABG, 12.9%, P < 0.001). 17) In 2012, a large-scale randomized trial, the Future Revascularization Evaluation in Patients with Diabetes Mellitus (FREEDOM) trial, was conducted. A total of 1900 diabetic patients with MVD were randomly assigned to CABG or PCI with mainly first-generation DES. 18) The incidences of all-cause mortality and myocardial infarction were significantly higher in the PCI group during the mean follow-up of 5 years compared with the CABG group (PCI, 26.6% versus CABG, 18.7%). Based on these results, the recent guidelines from the European Cardiology Society for the management of T2DM patients stated that PCI for MVD was a Class IIb indication for relieving symptoms as an alternative to CABG in patients with low complexity lesions that were defined by SYNTAX scores. 19) However, in the FREEDOM trial, almost all patients in the PCI group were treated with first-generation DES that were replaced by newergeneration DES in the current clinical practice. The newer generation DES have overcome the critical issue of the first generation DES; stent thrombosis, in particular, the everolimus-eluting stent (EES) reduced the rate of stent thrombosis compared with other DESs in a meta-analysis. 20) Bangalore and colleagues reported a meta-analysis of 68 randomized clinical trials to compare clinical outcomes in CAD patients with T2DM between those who received CABG and DESs, including SES, PES, and EES. 21) All-cause mortality was higher in the patients who received SES and PES compared with CABG, whereas the mortality rates in the EES group were similar to those of the CABG group (reference rate ratio to CABG, 1.31, 95% confidence interval; ). 22) These results should be carefully interpreted because they were generated from an indirect comparison of individual clinical trials. Recent clinical trials comparing EES and CABG in patients with a left main lesion (the Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL)) 21) or multivessel disease (the Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery Disease (BEST)) 23) provided conflicting results. In the EXCEL trial, a comparison of the efficacy between EES and CABG in patients with low to intermediate SYNTAX scores was performed. A total of 1905 patients were randomly assigned to each group. The primary endpoint, a composite of all-cause mortality, stroke or myocardial infarction at 3 years, occurred in 15.4% and 14.5% in EES group and CABG group (P = 0.02 for non-inferiority). Interestingly, the rate of short term events (30-day mortality, stroke or myocardial infarction) was lower in the EES group (4.9 versus 7.9%; HR 0.61; 95% confidence interval ), which was mainly driven by the lower incidence of myocardial infarction. The treatment effect for the primary endpoint was consistent in a prespecified sub-group analysis for diabetes mellitus. In the BEST trial comparing EES and CABG in multivessel disease, a total of 880 patients were analyzed. The primary endpoint (2-year mortality, myocardial infarction, or target vessel revascularization) occurred in 11.0% and 7.9% in the EES and CABG groups (P = 0.32 for non-inferiority). In the sub-group analysis for diabetes mellitus, the rate of the primary endpoint was significantly higher in the EES group. The discrepancy of the two clinical trials might be explained by the different populations (left main lesion or multivessel diseases), different complexity of the lesions, and different primary endpoints. However, CABG would be preferred in multivessel diseases considering the higher frequency of complete revascularization in CABG-treated patients and the previous randomized trial results. The results of the clinical trials comparing PCI with CABG in diabetic patients are summarized in the Table. Optimal Medical Therapy and Comprehensive Risk Management Because clinical outcomes in T2DM patients with CAD are poor, aggressive medical and non-pharmacological therapies are indispensable, regardless of the revascularization strategy pursued. The Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI-2D) trial examined and compared long-term clinical outcomes between medical therapy alone and revascularization by PCI or CABG in T2DM patients. 5) There was no significant difference between the PCI and CABG groups in cardiovascular events during the 5-year follow-up. These data indicated the importance of comprehensive risk management with glycemic control and administration of statins, angiotensin receptor blockers, angiotensin converting enzyme inhibitors, and antiplatelet therapy in T2DM patients with CAD. Guidelines for the management of diabetes mellitus from the American Diabetes Association, American College of Cardiology, and American Heart Association recommended the following prevention strategies for CAD: blood pressure 130/80 mmhg or less, low density lipoprotein cholesterol (LDL-C) below 100 mg/dl (below 70 mg/dl for CAD patients), and smoking cessation ) However, a recent study examining the achievement of risk management in the largescale clinical trials clinical outcomes utilizing revascularization and aggressive drug evaluation (COURAGE), BARI-2D, and FREEDOM, showed unexpectedly low achievement rates, which indicated the difficulty of comprehensive risk management. 27) One-year risk management achievement rates (LDL-C < 100 mg/dl, (70 mg/dl in the FREEDOM trial), systolic blood pressure < 130 mmhg, glycated hemoglobin < 7.0% and smoking cessation) were 18%, 23%, and 8% in the COURAGE, BARI-2D, and FREEDOM trials, respectively. 28) Although the achievement rate was not originally included in the clinical trial endpoints, these results prompted us to review our clinical practices regarding not only adherence to evidencebased medical therapy, but also whether risk management is
3 Vol 58 No 4 CAD AND DM 477 Table. Clinical Trials of PCI With CABG in Diabetic Patients Trial Type of trial Years of recruitment Number of subjects Type of PCI Endpoint Main results (PCI versus CABG) ARTS I 12) Randomized BMS 1 year freedom from death, stroke, MI or revascularization) 63.4 versus 84.4% (P < 0.001) MASS II 13) Randomized N/A 1 year death 5.3 versus 6.8% (P = 0.5) BARI-2D 14) Randomized Comparison between revascularization and medical st DES; 34.7% BMS; 56.0% Others; 9.3% 5 year freedom from death, MI, repeat revascularization PCI versus medical (77.0 versus 78.9; P = 0.15) CABG versus medical (77.6 versus 69.5%; P = 0.01) P for interaction CARDIa 18) Randomized st DES; 61% BMS; 31% 1 year death, stroke, or MI 13.0 versus 10.5% (P = 0.39) SYNTAX 15) Randomized st DES 5 year death, stroke, MI, or revascularization 46.5 versus 29.0% (P < 0.001) FREEDOM 16) Randomized st DES 1) 5 year death 2) 5 year death, nonfatal MI, or nonfatal stroke 1) 16.3 versus 10.9% (P = 0.049) 2) 26.6 versus 18.7% (P = 0.005) PCI indicates percutaneous coronary intervention; CABG, coronary artery bypass grafting; DES, drug-eluting stent; ARTS, Arterial Revascularization Therapies Study; BMS, bare metal stent; MACE, major adverse cardiovascular event; MI, myocardial infarction; MASS, Medicine, Angioplasty, or Surgery Study; and 1st DES, first generation DES.
4 478 NAITO, ET AL Int Heart J July 2017 properly achieved. Furthermore, non-pharmacotherapies including exercise, diet, and smoking cessation should be performed. Regarding the efficacy of strict glucose control with antidiabetic drugs on reducing cardiovascular events, large-scale randomized trials conducted in the early 2000s have shown that intensive glucose control did not consistently reduce cardiovascular events. 27,29,30) Since 2006, dipeptidyl peptidase-4 (DPP-4) inhibitors have been available as novel anti-diabetic drugs, which had a different mechanism of glucose-lowering compared with other agents such as sulfonylurea. To date, the results from 3 large-scale clinical trials (SAVOR, EXAINE and TECOS) using different DPP-4 inhibitors have been reported (Figure 1) ) A consistent finding was that the DPP-4 inhibitor group was non-inferior to conventional glucose-lowering therapy for the primary outcomes of cardiovascular death, myocardial infarction, stroke, and/or hospitalization for unstable angina. However, hospitalization for heart failure was more likely in the DPP4 inhibitor group in SAVOR and EXAMINE, which was not observed in TECOS. Another class of novel anti-diabetic drugs is the glucagon-like peptide-1 (GLP1) receptor agonists that stimulate insulin secretion in a glucose-dependent manner and reduce glucagon secretion. A large-scale clinical trial has compared the efficacy of lixisenatide to that of the control on cardiovascular outcomes in patients with T2DM and ACS. This trial was designed to investigate both the noninferiority and superiority of lixisenatide to controls, however, it could only demonstrate the noninferiority. On the other hand, two large clinical trials (LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial and SUSTAIN-6 (Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes)), which aimed to assess the primary prevention effect of a glucagon-like peptide 1 analogue added to standard care compared to placebo in T2DM, showed a statistically significant reduction in a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. In the LEADER trial, a total of 9340 patients with T2DM were randomly assigned to liraglutide with standard care or placebo. The primary endpoint (a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 13.0% and 14.9% in the liraglutide group and the placebo group during the median follow-up of 3.8 years (hazard ratio 0.87; 95% confidence interval ) (Figure 2). 34) In the SUSTAIN-6 trial, a total of 3297 patients with T2DM, 83.0% of which had cardiovascular disease, were randomly allocated to semaglutide added to standard care or placebo. The rate of a composite outcome (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) was significantly lower in the semaglutide group (hazard ratio 0.74, 95% confidence interval ). 35) The other novel anti-diabetic drug was a sodium glucose cotransporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption and results in increased urinary glucose excretion as well as diuresis. Empagliflozin, a selective inhibitor of SGLT2, reduces glycated hemoglobin, systolic blood pressure without a heart rate increase, and body weight. In 2015, a striking result was reported by the EMPA-REG OUT- COME trial whose aim was to examine the effects of empagliflozin on cardiovascular events compared to standard-of-care therapy. They demonstrated the superiority of empagliflozin in reducing cardiovascular events, in particular cardiovascular death and hospitalization for heart failure (Figure 3). 36) These recent clinical trials (EMPA-REG, LEADER, and SUSTAIN 6) have shed light on the cardiovascular protective effect of Figure 1. Cardiovascular outcomes for DPP-4 inhibitors. Three DPP-4 inhibitors were consistently non-inferior to conventional glucose-lowering therapy for the primary endpoints of cardiovascular death, myocardial infarction, stroke, and/or hospitalization for unstable angina.
5 Vol 58 No 4 CAD AND DM 479 Figure 2. Cardiovascular event rate in the LEADER trial. The rate of the primary outcome (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) was significantly lower in the Liraglutide group. novel anti-diabetic agents. Considering that patients with T2DM tend to have macroand microvascular complications, and the clinical outcomes of CAD patients are poor, interventions are desirable during the earlier stages of T2DM, such as impaired glucose tolerance (IGT). Progression to diabetes was observed in 10% of IGT patients. 37) However, it has not been fully elucidated whether IGT in CAD patients could be a treatment target for secondary prevention. Also, the effects of anti-diabetic agents including SGLT2 inhibitors and GLP-1 receptor agonists on reducing progression to diabetes or the incidence of cardiovascular events in this subset of patients are undetermined. Nevertheless, non-pharmacological therapies such as nutrition and exercise are important even in IGT patients. Previous studies reported that about one-third of CAD patients who had not been diagnosed with diabetes were actually diabetic. 38,39) Thus, aggressive surveys for diabetes and IGT are needed in CAD patients. In current clinical practice, although diabetes testing with fasting blood glucose and glycated hemoglobin are routinely checked, the glucose tolerance test is not frequently performed in CAD patients unless fasting blood glucose or glycated hemoglobin levels are above the upper limits of normal. To detect diabetes at an earlier stage, diabetes testing with blood glucose, glycated hemoglobin, and glucose tolerance are considerably important. Conclusions: In this review, the selection of appropriate coronary revascularization therapies and optimal medical therapy for comprehensive risk management in T2DM patients with CAD are described. When selecting revascularization strategies in this subset of patients, cardiologists and cardiac surgeons must thoroughly discuss as a heart team, based on not only the complexity of the lesions but also the characteristics of the patient. Comprehensive risk management with medical and non-pharmacological therapies should be performed and confirm whether risk management is properly achieved. Novel anti-diabetic drugs (SGLT2 inhibitors and GLP1 antagonists) could be beneficial in reducing cardiovascular events, which might play an important role in optimal medical therapy. Furthermore, non-pharmacological interventions with exercise, calorie intake restriction, and smoking cessation might also be beneficial in preventing the development and progression of atherosclerosis. Figure 3. Cardiovascular event rate in the EMPA-REG OUTCOME trial. The rate of the primary outcome (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) was significantly lower in the Empagliflozin group. References 1. Center for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, Atlanta, GA: U. S. Department of Health and Human Services, Centers for Disease Control and Prevention, Available at: pubs/pdf/ndfs_2011.pdf Accessed May 12, Hammoud T, Tanguay JF, Bourassa MG. Management of coronary artery disease: therapeutic options in patients with diabetes. J Am Coll Cardiol 2000; 36: (Review) 3. Norhammar A, Malmberg K, Diderholm E, et al. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol 2004; 43: Creager MA, Lüscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003; 108: (Review) 5. Dagenais GR, Lu J, Faxon DP, et al; Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease. Circulation 2011; 123: Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxeleluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. New Engl J Med 2010; 362: Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: Babapulle MN, Joseph L, Bélisle P, Brophy JM, Eisenberg MJ. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004; 364: Bangalore S, Kumar S, Fusaro M, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ 2012; 345: e Abizaid A, Costa MA, Centemero M, et al; Arterial Revascularization Therapy Study Group. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 2001; 104:
6 480 NAITO, ET AL Int Heart J July Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol 2010; 55: Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013; 381: Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 2009; 373: Serruys PW, Morice MC, Kappetein AP, et al; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360: Mack MJ, Banning AP, Serruys PW, et al. Bypass versus drugeluting stents at three years in SYNTAX patients with diabetes mellitus or metabolic syndrome. Ann Thorac Surg 2011; 92: Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367: Rydén L, Grant PJ, Anker SD, et al; ESC Committee for Practice Guidelines (CPG), Zamorano JL, Achenbach S, Baumgartner H, et al; Document Reviewers, De Backer G, Sirnes PA, Ezquerra EA, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34: Baber U, Mehran R, Sharma SK, et al. Impact of the everolimuseluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol 2011; 58: Stone GW, Sabik JF, Serruys PW, Simonton CA, et al; EXCEL Trial Investigators. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. N Engl J Med 2016; 375: Bangalore S, Toklu B, Feit F. Outcomes With Coronary Artery Bypass Graft Surgery Versus Percutaneous Coronary Intervention for Patients With Diabetes Mellitus: Can Newer Generation Drug- Eluting Stents Bridge the Gap? Circ Cardiovasc Interv 2014; 7: Park SJ, Ahn JM, Kim YH, et al; BEST Trial Investigators. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med 2015; 372: American Diabetes Association. Standards of medical care in diabetes Diabetes Care 2012; 35: S (Review) 25. Smith SC Jr, Benjamin EJ, Bonow RO, et al; World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009; 53: Duckworth W, Abraira C, Moritz T, et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: Farkouh ME, Boden WE, Bittner V, et al. Risk factor control for coronary artery disease secondary prevention in large randomized trials. J Am Coll Cardiol 2013; 61: Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: Scirica BM, Bhatt DL, Braunwald E, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: White WB, Cannon CP, Heller SR, et al; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: Green JB, Bethel MA, Armstrong PW, et al; TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373: Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375: Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: Goldfine AB, Phua EJ, Abrahamson MJ. Glycemic management in patients with coronary artery disease and prediabetes or type 2 diabetes mellitus. Circulation 2014; 129: (Review) 38. Ishihara M, Inoue I, Kawagoe T, et al. Is admission hyperglycaemia in non-diabetic patients with acute myocardial infarction a surrogate for previously undiagnosed abnormal glucose tolerance? Eur Heart J 2006; 27: Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359:
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationControversies in Cardiac Surgery
Controversies in Cardiac Surgery 3 years after SYNTAX : Percutaneous Coronary Intervention for Multivessel / Left main stem Coronary artery disease Pro ESC Congress 2010, 28 August 1 September Stockholm
More informationHEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD
HEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD Author affiliations: Department of Cardiology, Hôpital Saint Joseph, Paris, France Address for correspondence: Michel Komajda,
More informationCoronary Revascularization for Patients with Severe Coronary Artery Disease: An Overview of Current Evidence and Treatment Strategies
Review J Jpn Coron Assoc 2015; 21: 267-271 Coronary Revascularization for Patients with Severe Coronary Artery Disease: An Overview of Current Evidence and Treatment Strategies Hiroki Shiomi, Takeshi Kimura
More informationMaster Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April
Master Class in Preventive Cardiology Focus on Diabetes and Cardiovascular Disease Geneva April 14 2011 Coronary interventions in patients with diabetes Lars Rydén Karolinska Institutet Stockholm, Sweden
More informationCite this article as:
doi: 10.21037/acs.2018. 05.12 Cite this article as: Ngu JM, Sun LY, Ruel M. Pivotal contemporary trials of percutaneous coronary intervention vs. coronary artery bypass grafting: a surgical perspective..
More informationImpact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary Intervention
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationRationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
More informationManagement of cardiovascular disease - coronary interventions -
Master Classes in Preventive Cardiology I Management of diabetes in patients with CVD European Heart House Management of cardiovascular disease - coronary interventions - Francesco Cosentino MD, PhD, FESC
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationCoronary Stent Choice in Patients With Diabetes Mellitus
Rome Cardiology Forum 2014 Coronary Stent Choice in Patients With Diabetes Mellitus Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More informationLEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationDiabetic Patients: Current Evidence of Revascularization
Diabetic Patients: Current Evidence of Revascularization Alexandra J. Lansky, MD Yale University School of Medicine University College of London The Problem with Diabetic Patients Endothelial dysfunction
More informationLeft Main PCI vs. CABG: Real World
Management of Patients with Stable CAD Left Main PCI vs. CABG: Real World Marco Roffi, MD, FESC University Hospital Geneva, Switzerland SYNTAX-LMT The SYNTAX trial included a pre-specified subgroup of
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More informationUnprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality
Unprotected Left Main Coronary Artery Disease in Patients With Low Predictive Risk of Mortality Shun Watanabe, MD, Tatsuhiko Komiya, MD, Genichi Sakaguchi, MD, PhD, and Takeshi Shimamoto, MD, PhD Department
More informationSurgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome
Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Chris C. Cook, MD Associate Professor of Surgery Director, CT Residency Program, WVU ACOI 10/17/18 No Disclosures
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationUnprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
More informationPCI vs. CABG From BARI to Syntax, Is The Game Over?
PCI vs. CABG From BARI to Syntax, Is The Game Over? Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea PCI vs CABG Multi-Vessel Disease
More informationPCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France
PCI for Left Main Coronary Artery Stenosis Jean Fajadet Clinique Pasteur, Toulouse, France Athens, October 19, 2018 Left Main Coronary Artery Disease Significant unprotected left main coronary artery disease
More informationJournal of the American College of Cardiology Vol. 47, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 47, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.102
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationReview. Open Access. Beom Jun Lee 1, Peter Herbison 2, Cheuk-Kit Wong 1. 1 Introduction
Journal of Geriatric Cardiology (2014) 11: 83 89 2014 JGC All rights reserved; www.jgc301.com Review Open Access Is the advantage of coronary bypass graft surgery over percutaneous coronary intervention
More informationHCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic
More informationΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ
ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ Νίκος Μεζίλης MD, FESC Κλινική Άγιος Λουκάς Why diabetes is associated with restenosis endothelial dysfunction metabolic alterations accelerated platelet deposition
More informationStephen Clement M.D. CDE Medical Director, Endocrine Services Inova Fairfax Hospital
Stephen Clement M.D. CDE Medical Director, Endocrine Services Inova Fairfax Hospital Financial Disclosures Consulting Panel for GSK on Hepatitis Vaccines Case Study BH is a 67 y/o female with T2 DM for
More informationQuality of Life After Everolimus- Eluting Stents or Bypass Surgery for Treatment of Left Main Coronary Artery Disease:
Quality of Life After Everolimus- Eluting Stents or Bypass Surgery for Treatment of Left Main Coronary Artery Disease: Results from the EXCEL Trial Suzanne J. Baron MD MSC on behalf of the EXCEL Investigators
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationCARDIOVASCULAR RISK FACTOR CONTROL IN TYPE 2 DIABETES MELLITUS AND NEW TRIAL EVIDENCE
CARDIOVASCULAR RISK FACTOR CONTROL IN TYPE 2 DIABETES MELLITUS AND NEW TRIAL EVIDENCE *Peter M. Nilsson Department of Clinical Sciences, Lund University, Skåne University Hospital, Malmö, Sweden *Correspondence
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationCV outcomes Studies and Implications for diabetes management. Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH
CV outcomes Studies and Implications for diabetes management Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH Case 49 y female with the following medical problems DM typ2 Hypertension
More informationSurgery Grand Rounds
Surgery Grand Rounds Coronary Artery Bypass Grafting versus Coronary Artery Stenting Charles Ted Lord, R1 Coronary Artery Disease Stenosis of epicardial vessels Metabolic & hematologic Statistics 500,000
More informationCardiovascular outcome studies with glucagon-like peptide 1 receptor agonists what will REWIND add?
Editorial Page 1 of 5 Cardiovascular outcome studies with glucagon-like peptide 1 receptor agonists what will REWIND add? Keith C. Ferdinand, Indrajeet Mahata Department of Medicine, Tulane School of Medicine,
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More informationΑγγειοπλαστική σε διαβητικούς ασθενείς
Αγγειοπλαστική σε διαβητικούς ασθενείς Σταύρος Χατζημιλτιάδης Επίκουρος Καθηγητής Καρδιολογίας Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Νοσοκομείο ΑΧΕΠΑ Risk of Cardiovascular Outcomes in Diabetics Shramm
More informationLeft Main Intervention: Where are we in 2015?
Left Main Intervention: Where are we in 2015? David A. Cox, MD FSCAI Director, Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown, PA Fall Fellows Course Laa
More informationReferences List. References cited on CVInflammation.com
References List References cited on CVInflammation.com 1. Cannon CP, Braunwald E, McCabe CH, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22
More informationBetter CABGs vs Better PCI Devices
CABG vs PCI 2017 Multivessel Coronary Disease Better CABGs vs Better PCI Devices ACC New York, Dec 8, 2017 No Disclosures CABG vs PCI 2017 Stable Multivessel Coronary Disease 1. Are These The two Critical
More informationDESs in Multivessel Disease
DESs in Multivessel Disease Lessons learned from large registry experience. BY DANIEL W. CARLSON, MD, AND MARK A. TURCO, MD, FACC, FSCAI For patients with limitation of ordinary physical activity secondary
More informationNew Strategies for Cardiovascular Risk reduction in Diabetes
New Strategies for Cardiovascular Risk reduction in Diabetes Dr. Godwin LEUNG Tat Chi MB ChB(HK), MRCP (UK), FHKCP, FHKAM (Medicine) FRCP (Glasg), FACC Specialist in Cardiology % event as first CV event
More informationPCI for LMCA lesions A Review of latest guidelines and relevant evidence
HCS Working Group Seminars Met Hotel, Thursday 14 th February 2013 PCI for LMCA lesions A Review of latest guidelines and relevant evidence Vassilis Spanos Interventional Cardiologist, As. Director 3 rd
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationDapagliflozin and cardiovascular outcomes in type 2
EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes
More informationWhy are we doing cardiovascular outcome trials in type 2 diabetes?
MEDICAL GRAND ROUNDS VENU MENON, MD Heart and Vascular Institute, Cleveland Clinic BHUVNESH AGGARWAL, MD Heart and Vascular Institute, Cleveland Clinic TAKE-HOME POINTS FROM LECTURES BY CLEVELAND CLINIC
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationCoronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy
Coronary Artery Bypass Grafting Versus Coronary Implantation of Sirolimus-Eluting Stents in Patients with Diabetic Retinopathy Takayuki Ohno, MD, Shinichi Takamoto, MD, Noboru Motomura, MD, Minoru Ono,
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationClinical Investigations
Clinical Investigations Clinical Outcomes for Single Stent and Multiple Stents in Contemporary Practice Qiao Shu Bin, MD; Liu Sheng Wen, MD; Xu Bo, BS; Chen Jue, MD; Liu Hai Bo, MD; Yang Yue Jin, MD; Chen
More informationSupplementary Online Content
Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis
More informationA Meta-Analysis Of Randomized Controlled Trials With Coronary Drug-Eluting Stents Compared With Bare-Metal Stents
ISPUB.COM The Internet Journal of Cardiology Volume 3 Number 2 A Meta-Analysis Of Randomized Controlled Trials With Coronary Drug-Eluting Stents Compared With Bare-Metal Stents M Sondhi, A Jagannath, J
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationHelp the Heart. An Update on GLP-1 Agonists and SGLT2 Inhibitors. Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire
Help the Heart An Update on GLP-1 Agonists and SGLT2 Inhibitors Tara Hawley, PharmD PGY1 Pharmacy Resident Mayo Clinic Health System Eau Claire Mayo Clinic Grand Rounds May 16, 2017 2017 MFMER slide-1
More informationUpdate interventional Cardiology Hans Rickli St.Gallen
Update interventional Cardiology 2012 Hans Rickli St.Gallen 26.11.2012 Review of Literature ESC-Highlights TCT/AHA-Highlights Update interventional cardiology 2012 Structural Heart Disease Transcatheter
More informationDES in Diabetic Patients
DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase
More informationVCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital
VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital Complex PCI: Multivessel Disease George W. Vetrovec, MD. Kimmerling Chair of Cardiology VCU Pauley Heart Center Virginia
More informationTLR des Stents Actifs
TLR des Stents Actifs No Conflict of Interest Target Lesion Revascularization DES vs BMS Stettler C et al. Lancet 2007;370:937-48 N=18,023 58% 70% SES vs BMS: HR=0.30 (0.24-0.37), p
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationMise à Jour sur le traitement du Pluritronculaire Philippe Généreux, MD
Mise à Jour sur le traitement du Pluritronculaire Philippe Généreux, MD Columbia University Medical Center and The Cardiovascular Research Foundation, New York, USA Hôpital du Sacré-Coeur de Montréal,
More informationImportant LM bifurcation studies update
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Important LM bifurcation studies update I Sheiban E-mail: isheiban@yahoo.com Unprotected LM Percutaneous Revascularization What is important
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationLeft Main Intervention: Will it become standard of care?
Left Main Intervention: Will it become standard of care? David Cox, MD FSCAI, FACC Director, Interventional Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown,
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationPathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL
Pathology of percutaneous interventions (PCI) in coronary arteries Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Percutaneous Coronary Intervention (PCI) Definition: transcatheter opening of
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationDRUG ELUTING STENTS. Cypher Versus Taxus: Are There Differences? Introduction. Methods SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C.
DRUG ELUTING STENTS Cypher Versus Taxus: Are There Differences? SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C. From the Cardiology Practice and Hospital, Munich, Germany Today, drug-eluting stents (DES) are
More informationΔημήτριος Αγγοσράς, FETCS
ΣΕΜΙΝΑΡΙΟ ΟΜΑΔΩΝ ΕΡΓΑΣΙΑΣ Δημήτριος Αγγοσράς, FETCS Επίκοσρος Καθηγηηής Καρδιοτειροσργικής Ιαηρική Πανεπιζηημίοσ Αθηνών Πανεπιζηημιακό Γενικό Νοζοκομείο Αηηικόν Randomized Controlled Trials (RCTs) Why
More informationClinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at a Tertiary Medical Center
Aging Research Volume 2013, Article ID 471026, 4 pages http://dx.doi.org/10.1155/2013/471026 Clinical Study Age Differences in Long Term Outcomes of Coronary Patients Treated with Drug Eluting Stents at
More informationFor Personal Use. Copyright HMP 2014
Original Contribution Long-Term Safety and Efficacy of the Everolimus-Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice Israel M. Barbash, MD, Sa ar Minha,
More informationCase Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)?
Cronicon OPEN ACCESS CARDIOLOGY Case Report Left Main Stenosis. Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft Surgery (CABG)? Valentin Hristov* Department of Cardiology, Specialized
More informationSupplementary Online Content
Supplementary Online Content Amin AP, Spertus JA, Cohen DJ, Chhatriwalla A, Kennedy KF, Vilain K, Salisbury AC, Venkitachalam L, Lai SM, Mauri L, Normand S-LT, Rumsfeld JS, Messenger JC, Yeh RW. Use of
More informationMultivessel Coronary Artery Disease : CABG. Zürich, F. Siclari MD
Multivessel Coronary Artery Disease : CABG Zürich, 10.06.2015 F. Siclari MD Coronary Artery Ruptured Plaque Pathological process with definite subsequent vascular changes most of them irreversible CABG
More informationBioresorbable polymer drug-eluting stents in PCI
EARN 3 FREE CPD POINTS CARDIOVASCULAR Leader in digital CPD for Southern African healthcare professionals The BIOFLOW-V trial, using the Orsiro ultrathin strut stent with biodegradable polymer, showed
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationBenefit of Performing PCI Based on FFR
Benefit of Performing PCI Based on FFR William F. Fearon, MD Associate Professor Director, Interventional Cardiology Stanford University Medical Center Benefit of FFR-Guided PCI FFR-Guided PCI vs. Angiography-Guided
More informationAdecade ago, many cardiac surgeons believed
CABG for Multivessel CAD Recent studies show that CABG is still preferred over PCI for most patients. BY SUBHASIS CHATTERJEE, MD; JOHN C. ALEXANDER, MD; AND PAUL J. PEARSON, MD, PHD Adecade ago, many cardiac
More information2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More information